Diligence memo · auto-generated · as of July 2, 2026
Scout Bio, Inc.
Scout Bio, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Scout Bio, Inc. operates in Biotech / Pharma, based in PHILADELPHIA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Scout Bio, Inc. has raised $34M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2019-03-29.
Most recent recorded round closed around 2021-10-01.
Valuation (modeled)modeled
Provath models Scout Bio, Inc. at approximately $104M (range $9.7M–$316M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.20× the median modeled value of Series B Biotech / Pharma companies in 2019–2021 (11 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 22 months.
Last raise 4.7 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round was 4.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 85% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 70% of those peers.
Closest niche peers: Mantra Bio, Inc., Front Range Biosciences, Inc., Nido Biosciences, Inc., LifeVault Bio, Inc., Pharmajet, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.